lp-98
Small moleculeexperimental
Clinical trial activity
2 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Jul 13, 2023 (NCT05933824)
Timeline
2020s
- Jan 1, 2023
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- GP41INHIBITOR
HIV1 ENV inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06560489 | Phase 1/Phase 2 (Phase 2) | Sep 2, 2024 | Chinese Academy of Medical Sciences, Shanxi Kangbao Pharmaceutical company, Zhengzhou University |
| NCT05933824 | Phase 1 | Jul 13, 2023 | Chinese Academy of Medical Sciences, Shanxi Kangbao Pharmaceutical company, Zhengzhou University |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Chinese Academy of Medical Sciences | Academic/Hospital | 2 | 0 | 2 | 2023 |
| Shanxi Kangbao Pharmaceutical company | For profit | 2 | 2 | 2 | 2023 |
| Zhengzhou University | Academic/Hospital | 2 | 0 | 2 | 2023 |
3 organizations
Page 1 / 1